ArticleSignal transduction and targeted therapy2026
miRNAs as cell-intrinsic epigenetic regulators in muscle in type 2 diabetes.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
miRNAs are important metabolic regulators and are altered at both the cellular and secreted levels in diseases, including type 2 diabetes (T2D). However, to what extent these alterations are in response to factors in the in vivo milieu or are cell-intrinsic remains unclear. Here we used a disease-in-a-dish model in which iPSCs from T2D patients and controls were differentiated into myoblasts (iMyos), and their cellular and secreted miRNAs were profiled. We found that iMyos from T2D donors exhibit cell-intrinsic alterations in miRNA expression and secretion in small extracellular vesicles (sEVs)/exosomes. Integrating miRNA-predicted targets with transcriptomic and proteomic data revealed that miRNAs altered in T2D iMyos were associated with coordinated changes in their predicted targets, but with a much greater impact on protein than on mRNA levels. This effect was validated by miRNA overexpression in control iMyos. The upregulated miRNAs targeted pathways related to aerobic respiration, membrane trafficking, and RNA metabolism. Even more marked changes were observed in sEV-associated miRNAs secreted by T2D iMyos, indicative of T2D-associated effects on miRNA sorting and release. Target genes of secreted miRNAs altered in T2D iMyos were enriched in metabolic pathways including insulin signaling and mitochondrial metabolism. Consistent with this, sEVs derived from control iMyos increased glucose uptake and mitochondrial function in recipient human white adipocytes, whereas sEVs from T2D iMyos did not. Thus, in T2D, muscle exhibits cell-intrinsic alterations in expression and secretion of miRNAs, which function as epigenetic regulators of protein expression locally, as well as potentially in distal tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.